Aurora-2 is a key member of a closely related sub-group of serine/threonine kinases that play important roles in the completion of essential mitotic events. Aurora-2 is oncogenic and amplified in various human cancers and could be an important therapeutic target for inhibitory molecules that would disrupt the cell cycle and block proliferation. We report the first crystal structure of Aurora-2 kinase in complex with adenosine. Analysis of residues in the active site suggests differences with structurally and biologically related protein kinases. The activation loop, which contains residues specific to the Aurora family of kinases, has a unique conformation. These results provide valuable insight into the design of selective and highly potent ATP-competitive inhibitors of the Aurora kinases.
Introduction
Protein kinases play important roles in promoting or retarding transitions between different stages and checkpoints of the cell cycle [1] . In humans, a closely related subgroup of three serine/threonine protein kinases, the Aurora kinases [2, 3] , are believed to play a key role in protein phosphorylation events that regulate the mitotic phase of cell cycle. The human Aurora kinases display distinct subcellular locations during mitosis. Aurora-2, alternatively known as Aurora-A, is upregulated during the M phase of the cell cycle and localizes to the spindle pole during mitosis, suggesting a possible involvement in centrosomal functions. Whilst Aurora-2 activity is maximal during prophase, Aurora-1 (Aurora-B) appears to play an important role during chromatid separation and formation of the cleavage furrow in anaphase and telophase. The role of Aurora-3 (Aurora-C) is less clear, but it has been shown to localize to centrosomes during mitosis from anaphase to cytokinesis. The Aurora kinases are specifically degraded by proteosome activity [2, 4] upon exit from mitosis. Homologous members of the Aurora kinase family have been identified in a number of different organisms [5, 6] .
The Aurora kinases are overexpressed in several types of human cancer cells, such as colon, breast and other solid tumors [7, 8, 9] . More importantly, both the Aurora-1 and Aurora-2 genes are amplified in breast and colorectal cancers, while the Aurora-3 gene is located in a region that is rearranged or deleted in several cancer cells [10, 11] . Overexpression of Aurora-2 in rodent fibroblasts induces transformation, indicating that Aurora-2 is oncogenic [7] . Recently, Aurora-2 mRNA expression has been linked to chromosomal instability in human breast cancers [12] . Inhibition of Aurora kinase activity in mammalian cells leads to abnormal cell growth and polyploidy [13] . Thus the Aurora kinases could be good targets for therapeutic treatment of cancer.
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The Aurora kinases share a common sequence and structure, consisting of a highly conserved C-terminal catalytic domain and a short N-terminal domain that varies in size [2] .
The N-terminal domains of Aurora-1, Aurora-2 and Aurora-3 have limited sequence similarity, and it has been proposed that they make interactions with other proteins [14, 15] that facilitate relocation of the Aurora enzymes from the cytoplasm to the nucleus during mitosis. The catalytic domain of Aurora-family kinases contains a short C-terminal tail sequence (residues 390-403) which may aid proteosome degradation of the enzymes at the end of mitosis [4, 16] . Specific degradation of the Aurora enzymes upon exit from mitosis is consistent with their very low cellular levels in G1 phase.
As central mediators of cell mitosis and progression through the G 2 /M phase of the cell cycle, Aurora protein kinases are potential targets for inhibitory molecules that would block cell proliferation and may therefore be useful as cancer therapeutics. It has been established that highly specific ATP-competitive inhibitors can be obtained against a number of different kinases with clinical uses as agents in the treatment of cancer [17] .
Understanding the molecular constraints of the ATP-binding site of Aurora-2 and the structural basis for interactions with adenosine is an essential step in designing inhibitors for this sub-family of kinases that are both selective and potent. We have determined the crystal structure of the C-terminal catalytic kinase domain of Aurora-2 bound to adenosine at 2.9Å resolution. This is the first report of a crystal structure of a member of the Aurora family of protein kinases.
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Results

Overall structure and homology with other protein kinases
The catalytic domain of Aurora-2_has the typical bi-lobal kinase fold [18, 19] , comprised of an N-terminal β-strand domain (residues 127-215) and a C-terminal α-helical domain (residues 216-385) (Figure 1 ). These domains are linked together by a hinge region (residues 210-216) which plays an important part in forming the catalytic active site ( Figure   2 ). In the refined crystal structure, a number of residues located at the N-and C-termini of the kinase domain (107-127 and 389-403, respectively) exhibited poor electron density and these residues could not be placed in electron density. The C-terminus of all Aurora-family kinases contain a conserved amino acid sequence, centred around residues R371 and L374, located in a structured loop region at the surface of the kinase domain, approximately 30Å from the catalytic active site. This degradation motif protrudes from the globular kinase fold and is ideally positioned for recognition by another protein or co-factor.
Comparison of Aurora-2 with other protein kinases reveals that its overall structure and topology is closely related to both the SRC family of tyrosine kinases [20, 21] and the AGC family of kinases [18] . R.m.s. deviations calculated for 241 C-alpha atoms for superposition of Aurora-2 with SRC and PKA are 4.8 Å and 4.0Å, respectively. For all residues located within a 5Å sphere of the Aurora-2 active site, the r.m.s deviations with SRC and PKA [18] are 1.0Å and 1.4Å, respectively. Adenosine binds in a deep cleft at the interface of the α-helical and β-strand domains, as observed for other protein kinases [18, 20, 21] . Specific hydrogen bonds are made between the purine ring of adenosine and the hinge region of the kinase (Figure 2a ). The active site cleft is bounded by the glycine-rich loop, which contains the consensus kinase sequence Gly-X-Gly-X-X-Gly (residues 140-149 in Aurora-2) and the activation loop. As observed in the structures of CSK kinase by guest on January 28, 2018 http://www.jbc.org/ Downloaded from Aurora-2 crystal structure: 13/9/028:35 AM 6 bound to staurosporine [22] and the SRC family kinase HCK bound to AMPPNP [20] , a part of the Aurora-2 activation loop (defined as residues 273-292) is disordered. Only residues 273-278 and 289-292 were clearly visible and have been included in the final model. Residue T288, which is phosphorylated during activation of Aurora-2, belongs to part of the disordered region and was not visible in electron density maps.
Catalytic activity of Aurora-2 is not regulated by the N-terminal domain
Limited in-vitro proteolysis of full length Aurora-2 by a selected panel of proteases (data not shown) combined with sequence and secondary structure alignment of Aurora-2 and related protein kinases was used to identify residue E107 as part of the Aurora-2 polypeptide that spans the N-terminal and C-terminal catalytic sub-units. Accordingly, an expression construct comprising residues 107-403 was used for crystallographic studies.
The disordered nature of residues 107-126 in the final crystal structure suggests that this spanning polypeptide linker is particularly long and flexible in Aurora-2. Comparison of the Aurora-1 and Aurora-3 sequences in this region suggest that these enzymes have a much shorter polypeptide linker.
The enzymatic properties of both the full-length and truncated (107-403) Aurora-2 proteins were compared to check whether the N-terminus is required for catalytic activity.
Using purified enzymes, which were first activated by pre-incubation with ATP, a photometric assay was used to determined the Km and kcat values for ATP as well as the This result indicates that the truncated enzyme used in this crystallographic study will reflect the structure of the ATP-binding site of Aurora-2.
This behaviour is different to many other kinases, where additional protein domains or polypeptide extensions appended to the catalytic kinase domain modulate the binding of ATP in the catalytic active site or the rate of enzyme catalysis [23, 24] . It has been suggested that the N-terminal domains of Aurora-1 and Aurora-2 may mediate interactions with other proteins, which helps translocation of these kinases to the nucleus during mitosis [25] . We have shown that the C-terminal domain of Aurora-2 is able to function as an independent catalytic sub-unit, and this supports a distinct role for the N-terminal domain during the cell cycle.
Structure of the ATP binding site
The ATP-binding pocket of Aurora-2 is hydrophobic and has several features that have been observed in other protein kinases. The 6-amino and 1-imido groups of adenosine bind to the hinge region of the Aurora-2 active site through direct hydrogen bonds with the mainchain amides of residues E211 and A213 (hydrogen-bond distances of 2.62Å and 2.63Å), respectively. This part of the hinge region is structurally conserved in many other kinases and these interactions with adenosine are very similar to those seen between adenosine [26] or ATP-analogues [20, 21, 22] and other protein kinases. The fluoro-phenyl pocket (see Figure 2) , so-named after a series of MAP kinase inhibitors which utilize this active site pocket [27] , is created by residues L210 and E211 (in the hinge region), V147 (in glycine-rich loop), A160 and L194 in Aurora-2. The purine ring of adenosine is positioned between residue L263, located in the floor of the active site and a hydrophobic surface created by residues L137 and V147 (from the glycine-rich loop) and residue A160. Figure   2 .
When compared to similar serine/threonine and tyrosine kinases, Aurora-2 displays several unique features which can be exploited in the design of highly selective inhibitors, making it an extremely attractive target for structure-based drug design. In the vicinity of the purine base of adenosine, there are two pockets that could be exploited for the design of new inhibitors that bind to Aurora-2 with increased affinity and selectivity over closely related kinases. The 6-amino group of adenosine points towards a deep hydrophobic fluoro-phenyl pocket formed by the flexible glycine-rich loop and the hinge region. This pocket contains several residues that are not conserved in SRC, GSK-3β and CDK-2.
Corresponding to residue L210 in Aurora-2 (see Figure 2a ), SRC and CDK-2 have threonine and phenylalanine residues at this position, respectively. F80 in CDK-2 restricts the size and entrance to this hydrophobic pocket and T338, present in SRC, presents a unique hydrogen-bonding group and a less hydrophobic surface at the entrance to this pocket. Thus, the flurophenyl pocket introduces the possibility of exploiting differences in shape and charge to obtain Aurora-2 selectivity.
When compared to GSK-3β and CDK-2, the hinge regions of Aurora-2 and SRC contain a single Glycine insertion (residue 216 in Aurora-2), which changes the size and The corresponding residues, E127 and D86 in cAMP-dependent protein kinase [18, 26] and CDK-2, respectively, make a specific hydrogen bonds with the 2'-OH group of ATP or adenosine. In Aurora-1 and Aurora-3, residue E217 would also be expected to make a hydrogen bond with the 2'-OH group of adenosine. In Aurora-2, T217 acts to stabilize the tertiary conformation of the C-terminal kinase lobe by participating in a hydrogen-bonding network with residues P259 and L269.
Unique conformation of the activation loop
Within the Aurora family, the catalytic domain and the kinase activation loop sequences are highly conserved, as previously observed in other protein kinase family's [31] . Sequence comparison of the Aurora-family kinases in the activation loop region, and comparison with sequences of other related kinases, have identified a conserved threonine residue, T288 in Aurora-2, as a potential phosphorylation site [2] . Residue T288 is disordered in this crystal structure. Mutation of T288 in Aurora-2 to aspartic acid, which mimics a constitutive phosphorylation, generates a hyperactive kinase [7] , indicating that this residue is the likely target for an activating kinase. Residue T288 is located approximately 25Å from the ATP-binding site of Aurora-2.
Crystal structures of cAMP-dependent protein kinase complexed with ATP or adenosine and a peptide substrate are believed to represent the bioactive conformations of protein kinases [18, 26] . Residues 273-278, located at the N-terminal-end of the activation loop in by guest on January 28, 2018
http://www.jbc.org/ Downloaded from Aurora-2 crystal structure: 13/9/028:35 AM 10 Aurora-2, are clearly visible in this crystal structure and adopt a unique conformation. In the cAMP-dependent kinase crystal structures and all other kinase crystal structures, the activation loop adopts an extended conformation, irrespective of whether an activated or dephosphorylated kinase was used for crystallization. In this Aurora-2 crystal structure, residues D274, F275, G276 and W277 adopt a closed conformation whereby residue W277 folds into the active site pocket to create a novel hydrophobic binding pocket. The side chain of residue W277 hydrogen bonds to the O5' position of adenosine. By homology with other kinases, the salt bridge interaction between the catalytic residues D274
and K162 in Aurora-2, which is seen in most other kinase structures, is not observed (Figure 2a ). Despite this, the N-terminal and C-terminal lobes of the catalytic domain in Aurora-2 appear to come together to form a closed conformation of this enzyme that is not catalytically active. This is reflected in the αC-helix of Aurora-2 (residues 174-188; see Figure 1 ) which is partially ordered in this crystal structure and occupies a similar closed position and orientation to the αC-helix in the active structure of cAMP-dependent kinase.
However, the conserved glutamate residue in helix C, residue E181 in Aurora-2, is incorrectly aligned for catalysis and does not does not make a hydrogen bond with K162, as observed for cAMP-dependent kinase.
The orientation of residue W277 is stabilized by interactions with residue F144 in the flexible glycine rich loop and residue F275. Residue F144 is conserved in many other kinases, however similar interactions with the activation loop have not been reported. W277
in Aurora-2 corresponds to F187 in cAMP-dependent kinase and L407 in SRC kinase.
These residues adopt a distinctly different orientation with respect to the glycine-rich loop residues. W277 is conserved in all three human Aurora kinases and all known Aurora-like sequences [2] . A search of the GenBank database [32] did not reveal any other kinases with a tryptophan located at this position. It is not clear how the conformation of this loop will change upon phosphorylation of residue T288.
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Discussion: Implications for inhibitor design
The catalytic domains of Aurora-1 and Aurora-3 share approximately 82% overall sequence homology with Aurora-2 and within the ATP-binding site the three human Aurora kinases are almost identical. In the sphere of protein residues surrounding the bound adenosine molecule, only residue 217, which is Threonine in Aurora2 and glutamic acid in both Aurora-1 and Aurora-3, is not conserved. In Aurora-2, the side chain of T217 makes a hydrogen bond with the mainchain of residue E260. This important role of T217 in stabilizing the tertiary structure of the C-terminal kinase lobe suggests that it is not a good target to achieve selectivity for Aurora-2, versus Aurora-1 and Aurora-3. Based on this crystal structure and structure-based sequence alignment of Aurora-1 and Aurora-3, it is expected that the design of small inhibitors that are selective for Aurora-2 will be very difficult.
It is also apparent from this crystal structure that within the ATP-binding site there are several pockets which could be exploited to gain selectivity for Aurora-2 over the closely related active site structures of CDK-2, GSK-3β and SRC kinases. In addition, by developing inhibitors that explore parts of the Aurora-2 active site it may be possible to use the novel hydrophobic binding site created at the interface of the activation and glycine-rich loops to gain increased selectivity. The unique kinase-adenosine and protein-protein interactions observed in this crystal structure should facilitate the design of novel Aurorakinase inhibitors for the treatment of cancer.
Materials and Methods
Expression and Purification. A truncated version of Aurora-2 (107-403) (the same sequence as GenBank AF011468) with an N-terminal hexa-histidine tag and a thrombin cleavage site was overexpressed in a baculovirus expression system. Aurora-2 was purified using Ni/NTA agarose metal affinity chromatography (Qiagen, Hilden, Germany) followed , and centrifuged at 100,000 x g prior to crystallization.
Inhibition Assay for Aurora-2. Aurora-2 kinase activity was assayed using a standard coupled enzyme system [33] . Data were reduced using MOSFLM [34] and CCP4 [35] . The structure was determined by molecular replacement [36] using a homology model of Aurora-2, based on the structure of cAMP-dependent protein kinase [19] . The initial molecular replacement solution was subject to multiple rounds of molecular dynamics refinement [37] in CNX and rebuilding with QUANTA. The bound adenosine molecule could be clearly seen in a difference-Fourier map calculated at 2.9Å resolution.
The refined atomic coordinates for this crystal structure have been deposited with the Protein Databank. by guest on January 28, 2018
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